TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/19/23 16:07 | 4/18/23 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Chu Yu-Waye | CA | O | Chief Me | S | -17 | 6.57 | 0 | -3 | -2 | 141 | D | |||||||||||||||
1/11/23 16:05 | 1/10/23 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Chu Yu-Waye | CA | O | Chief Me | S | -41 | 5.24 | 0 | -8 | -5 | 143 | D | |||||||||||||||
4/21/22 16:04 | 4/19/22 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Chu Yu-Waye | CA | O | Chief Me | S | -144 | 35.37 | 0 | -4 | -3 | 151 | D | |||||||||||||||
1/13/22 16:05 | 1/11/22 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Chu Yu-Waye | CA | O | SVP Clin | S | -192 | 48.51 | 0 | -4 | -3 | 122 | D | |||||||||||||||
12/13/21 17:53 | 12/10/21 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Chu Yu-Waye | CA | O | SVP Clin | S.d | -386 | 51.46 | 0 | -8 | -6 | 126 | D | |||||||||||||||
4/20/21 16:00 | 4/16/21 | FATE | Fate Therapeutics Inc | DE | Health | BioPrd | Biological Products, (No Diag | Chu Yu-Waye | CA | O | SVP Clin | S | -273 | 83.30 | 0 | -3 | -5 | 65 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |